Kintara Therapeutics
Kintara Therapeutics
KTRA
NASDAQ
2.12
USD
0.00%
About
Kintara Therapeutics, Inc. is a biopharmaceutical company focused on the development of new solid tumor cancer therapies. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death.
It has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product. Its product candidate, VAL-083, is a DNA-targeting agent intended to treat drug-resistant solid tumors, such as glioblastoma (GBM) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study.
VAL-083 is also used for various other indications..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.6M |
| Three Month Average Volume | 125.9M |
| High Low | |
| Fifty-Two Week High | 4.92 USD |
| Fifty-Two Week Low | 0.081 USD |
| Fifty-Two Week High Date | 11 Sep 2023 |
| Fifty-Two Week Low Date | 12 Mar 2024 |
| Price and Volume | |
| Current Price | 0.1867 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -1.93% |
| Thirteen Week Relative Price Change | -43.80% |
| Twenty-Six Week Relative Price Change | 68.79% |
| Fifty-Two Week Relative Price Change | -96.73% |
| Year-to-Date Relative Price Change | -7.04% |
| Price Change | |
| One Day Price Change | -1.27% |
| Thirteen Week Price Change | -39.85% |
| Twenty-Six Week Price Change | 85.59% |
| Five Day Price Change | -17.13% |
| Fifty-Two Week Price Change | -95.90% |
| Year-to-Date Price Change | 10.08% |
| Month-to-Date Price Change | -15.75% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.43203 USD |
| Book Value Per Share (Most Recent Quarter) | 0.10708 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.43203 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.10708 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.7159 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -9.27099 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -4.07969 USD |
| Normalized (Last Fiscal Year) | -9.27099 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -9.27099 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -4.07969 USD |
| Including Extraordinary Items (Last Fiscal Year) | -9.27099 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -4.07969 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.90721 USD |
| Cash Per Share (Most Recent Quarter) | 0.11484 USD |
| Cash Flow Per Share (Last Fiscal Year) | -9.23395 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.72332 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.55593 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -67.46% |
| Tangible Book Value (5 Year) | -32.98% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 78.93% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 97.68% |
| EPS Change (Trailing Twelve Months) | 65.31% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 14 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -6,351,000 |
| Net Debt (Last Fiscal Year) | -1,535,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -12,105,000 |
| Free Cash Flow (Trailing Twelve Months) | -7,270,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -147.03% |
| Return on Assets (Trailing Twelve Months) | -131.55% |
| Return on Assets (5 Year) | -220.94% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -227.91% |
| Return on Investment (Trailing Twelve Months) | -185.60% |
| Return on Investment (5 Year) | -329.97% |